Always keep an eye on insider buying.
After all, it’s the insiders that know their company the best. And if they’re putting their money where their mouths are, that’s telling.
Here are just a few stocks worth watching thanks to recent insider activity.
|
Company: Agree Realty (SYM: ADC) A real estate investment trust with a yield of 4.51%, Agree Realty (ADC) acquires and develops properties net leased to industry-leading, omnichannel retail tenants. As of March 31, the REIT owned and operated a portfolio of 2,161 properties, located in 49 states and containing approximately 44.9 million square feet of gross leasable area. Director John Rakolta Jr. recently bought another 20,000 shares for just over $1.18 million. Prior to this buy, he bought 20,102 shares for $1.14 million in February, and 20,430 shares for $1.164 million in February as well. |
Porter & Co.
Porter Stansberry’s 2024 Election Prediction
In this new documentary, legendary economist Porter Stansberry lays out exactly what’s going on in the 2024 election and why this could be America’s Last Election.
Click here to get all the details
|
Company: Biohaven (SYM: BHVN) Biohaven is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Director John Childs recently bought 28,400 shares of the stock for about $1.01 million. After pulling back from about $60 to $36, the stock is starting to show signs of life again. From its last traded price of $36.13, we’d like to see it retest $50 near term. |
Weiss Ratings
Bank Accounts in Danger
Dr. Martin Weiss has recently uncovered the government’s chilling new program that could radically change America forever.
It involves the Fed …
Your bank account …
And a Draconian set of rules that could install total financial surveillance.
This includes monitoring your every transaction and locking you out of your money for any reason …
Follow these three simple steps to protect your savings before it’s too late.
|
Company: Adverum Biotechnologies (SYM: ADVM) The company, which targets unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration just saw a significant shareholder buy 216,264 shares for just over $1.785 million. |
